-
2
-
-
65649119698
-
The influence of treatment in specialized centers on survival of patients with thalassemia major
-
PID: 19396857
-
Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M (2009) The influence of treatment in specialized centers on survival of patients with thalassemia major. Am J Hematol 84:317–318
-
(2009)
Am J Hematol
, vol.84
, pp. 317-318
-
-
Forni, G.L.1
Puntoni, M.2
Boeri, E.3
Terenzani, L.4
Balocco, M.5
-
3
-
-
5644257032
-
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia
-
COI: 1:CAS:528:DC%2BD2cXpvFait70%3D, PID: 15461618
-
Voskaridou E, Terpos E (2004) New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 127:127–139
-
(2004)
Br J Haematol
, vol.127
, pp. 127-139
-
-
Voskaridou, E.1
Terpos, E.2
-
4
-
-
79751538029
-
Bone disease and skeletal complications in patients with β thalassemia major
-
PID: 21035575
-
Haidar R, Musallam KM, Taher AT (2011) Bone disease and skeletal complications in patients with β thalassemia major. Bone 48:425–432
-
(2011)
Bone
, vol.48
, pp. 425-432
-
-
Haidar, R.1
Musallam, K.M.2
Taher, A.T.3
-
5
-
-
61849146917
-
Bone disease in thalassemia: a frequent and still unresolved problem
-
PID: 18505376
-
Vogiatzi MG, Macklin EA, Fung EB et al (2009) Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24:543–557
-
(2009)
J Bone Miner Res
, vol.24
, pp. 543-557
-
-
Vogiatzi, M.G.1
Macklin, E.A.2
Fung, E.B.3
-
6
-
-
44949213724
-
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia
-
COI: 1:CAS:528:DC%2BD1cXnt1amsbo%3D, PID: 18430624
-
Fung EB, Harmatz PR, Milet M, Multi-Center Iron Overload Study Group et al (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43:162–168
-
(2008)
Bone
, vol.43
, pp. 162-168
-
-
Fung, E.B.1
Harmatz, P.R.2
Milet, M.3
Multi-Center Iron Overload Study Group4
-
7
-
-
33644988157
-
Prevalence of fractures among the thalassemia syndromes in North America
-
COI: 1:STN:280:DC%2BD287ls1Sktw%3D%3D, PID: 16298178
-
Vogiatzi MG, Macklin EA, Fung EB et al (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38:571–575
-
(2006)
Bone
, vol.38
, pp. 571-575
-
-
Vogiatzi, M.G.1
Macklin, E.A.2
Fung, E.B.3
-
8
-
-
0032427820
-
Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major
-
PID: 10091149
-
Wonke B, Jensen C, Hanslip JJ et al (1998) Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 11:795–801
-
(1998)
J Pediatr Endocrinol Metab
, vol.11
, pp. 795-801
-
-
Wonke, B.1
Jensen, C.2
Hanslip, J.J.3
-
9
-
-
0032411621
-
Bone disease in beta-thalassaemia major
-
COI: 1:STN:280:DyaK1M7gtFeruw%3D%3D, PID: 9886298
-
Wonke B (1998) Bone disease in beta-thalassaemia major. Br J Haematol 103:897–901
-
(1998)
Br J Haematol
, vol.103
, pp. 897-901
-
-
Wonke, B.1
-
10
-
-
3242795997
-
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle
-
COI: 1:CAS:528:DC%2BD2cXktFGksro%3D, PID: 15068494
-
Morabito N, Gaudio A, Lasco A et al (2004) Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 19:722–727
-
(2004)
J Bone Miner Res
, vol.19
, pp. 722-727
-
-
Morabito, N.1
Gaudio, A.2
Lasco, A.3
-
11
-
-
79551518845
-
Use of bisphosphonates in the management of postmenopausal osteoporosis
-
COI: 1:CAS:528:DC%2BC3MXjsVKgsr4%3D, PID: 20946579
-
Papapoulos SE (2011) Use of bisphosphonates in the management of postmenopausal osteoporosis. Ann N Y Acad Sci 1218:15–32
-
(2011)
Ann N Y Acad Sci
, vol.1218
, pp. 15-32
-
-
Papapoulos, S.E.1
-
12
-
-
56349158692
-
Bisphosphonates: how do they work?
-
COI: 1:CAS:528:DC%2BD1cXhsVWmsbnJ, PID: 19028359
-
Papapoulos SE (2008) Bisphosphonates: how do they work? Best Pract Res Clin Endocrinol Metab 22:831–847
-
(2008)
Best Pract Res Clin Endocrinol Metab
, vol.22
, pp. 831-847
-
-
Papapoulos, S.E.1
-
13
-
-
84882845470
-
Treatment of male osteoporosis with bisphosphonates
-
Orwoll ES, Bilezikian JP, Vanderschueren D, (eds), Academic Press (Elsevier), London:
-
Giusti A, Papapoulos SE (2009) Treatment of male osteoporosis with bisphosphonates. In: Orwoll ES, Bilezikian JP, Vanderschueren D (eds) Osteoporosis in men: the effects of gender on skeletal health, 2nd edn. Academic Press (Elsevier), London, pp 667–679
-
(2009)
Osteoporosis in men: the effects of gender on skeletal health
, pp. 667-679
-
-
Giusti, A.1
Papapoulos, S.E.2
-
14
-
-
79960432551
-
Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis
-
COI: 1:CAS:528:DC%2BC3MXovVWis7g%3D, PID: 21637997
-
Rizzoli R, Reginster JY, Boonen S et al (2011) Adverse reactions and drug–drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91–104
-
(2011)
Calcif Tissue Int
, vol.89
, pp. 91-104
-
-
Rizzoli, R.1
Reginster, J.Y.2
Boonen, S.3
-
15
-
-
34848841461
-
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research
-
PID: 17663640
-
Khosla S, Burr D, Cauley J et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491
-
(2007)
J Bone Miner Res
, vol.22
, pp. 1479-1491
-
-
Khosla, S.1
Burr, D.2
Cauley, J.3
-
16
-
-
77955981091
-
Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies
-
COI: 1:CAS:528:DC%2BC3cXos1Chu70%3D, PID: 20493982
-
Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180
-
(2010)
Bone
, vol.47
, pp. 169-180
-
-
Giusti, A.1
Hamdy, N.A.2
Papapoulos, S.E.3
-
17
-
-
0036342860
-
Bisphosphonates in the treatment of thalassemia-induced osteoporosis
-
COI: 1:CAS:528:DC%2BD38Xns1entb4%3D, PID: 12181623
-
Morabito N, Lasco A, Gaudio A et al (2002) Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 13:644–649
-
(2002)
Osteoporos Int
, vol.13
, pp. 644-649
-
-
Morabito, N.1
Lasco, A.2
Gaudio, A.3
-
18
-
-
0346363162
-
Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis
-
PID: 14586797
-
Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402–408
-
(2003)
J Bone Miner Metab
, vol.21
, pp. 402-408
-
-
Pennisi, P.1
Pizzarelli, G.2
Spina, M.3
Riccobene, S.4
Fiore, C.E.5
-
19
-
-
33748757909
-
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BD28XhtVOhtL%2FJ, PID: 16956818
-
Voskaridou E, Anagnostopoulos A, Konstantopoulos K et al (2006) Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 91:1193–1202
-
(2006)
Haematologica
, vol.91
, pp. 1193-1202
-
-
Voskaridou, E.1
Anagnostopoulos, A.2
Konstantopoulos, K.3
-
20
-
-
33748957343
-
A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia
-
COI: 1:CAS:528:DC%2BD28XpvFalsLw%3D, PID: 16969592
-
Gilfillan CP, Strauss BJ, Rodda CP et al (2006) A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 79:138–144
-
(2006)
Calcif Tissue Int
, vol.79
, pp. 138-144
-
-
Gilfillan, C.P.1
Strauss, B.J.2
Rodda, C.P.3
-
21
-
-
84863468463
-
Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study
-
COI: 1:CAS:528:DC%2BC38XhtlehtrfN, PID: 22571408
-
Forni GL, Perrotta S, Giusti A et al (2012) Neridronate improves bone mineral density and reduces back pain in beta-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study. Br J Haematol 158:274–282
-
(2012)
Br J Haematol
, vol.158
, pp. 274-282
-
-
Forni, G.L.1
Perrotta, S.2
Giusti, A.3
-
22
-
-
54349085318
-
Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BD1cXhtl2gurrM, PID: 18698086
-
Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E (2008) Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 93:1588–1590
-
(2008)
Haematologica
, vol.93
, pp. 1588-1590
-
-
Voskaridou, E.1
Christoulas, D.2
Konstantinidou, M.3
Tsiftsakis, E.4
Alexakos, P.5
Terpos, E.6
-
23
-
-
40549136796
-
Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis
-
PID: 18253025
-
Voskaridou E, Christoulas D, Antoniadou L, Terpos E (2008) Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis. Acta Haematol 119:40–44
-
(2008)
Acta Haematol
, vol.119
, pp. 40-44
-
-
Voskaridou, E.1
Christoulas, D.2
Antoniadou, L.3
Terpos, E.4
-
24
-
-
84869509300
-
High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density
-
Voskaridou E, Christoulas D, Plata E et al (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res [Epub ahead of print]
-
(2012)
Horm Metab Res [Epub ahead of print]
-
-
Voskaridou, E.1
Christoulas, D.2
Plata, E.3
-
25
-
-
66049103776
-
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration
-
COI: 1:CAS:528:DC%2BD1MXntVGqsrY%3D, PID: 19407319
-
Voskaridou E, Christoulas D, Xirakia C et al (2009) Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 94:725–728
-
(2009)
Haematologica
, vol.94
, pp. 725-728
-
-
Voskaridou, E.1
Christoulas, D.2
Xirakia, C.3
-
26
-
-
72449149285
-
Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review
-
COI: 1:CAS:528:DC%2BD1MXhsFSqtLbO, PID: 19242634
-
Mamtani M, Kulkarni H (2010) Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 21:183–187
-
(2010)
Osteoporos Int
, vol.21
, pp. 183-187
-
-
Mamtani, M.1
Kulkarni, H.2
-
27
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
-
COI: 1:CAS:528:DyaK2sXisFCktQ%3D%3D, PID: 8950879
-
Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
28
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
-
COI: 1:CAS:528:DyaK1MXjsVWruw%3D%3D, PID: 9875874
-
Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082
-
(1998)
JAMA
, vol.280
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
29
-
-
0028851590
-
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group
-
COI: 1:CAS:528:DyaK28XkslehtA%3D%3D, PID: 7477143
-
Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443
-
(1995)
N Engl J Med
, vol.333
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Broll, J.3
-
30
-
-
0032896590
-
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group
-
COI: 1:CAS:528:DyaK1MXkt1CktrY%3D, PID: 10550467
-
Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468
-
(1999)
Osteoporos Int
, vol.9
, pp. 461-468
-
-
Pols, H.A.1
Felsenberg, D.2
Hanley, D.A.3
-
31
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
-
COI: 1:CAS:528:DyaK1MXmvFansr0%3D, PID: 10527181
-
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352
-
(1999)
JAMA
, vol.282
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
32
-
-
0035253489
-
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
-
COI: 1:CAS:528:DC%2BD3MXht1Wlu7g%3D, PID: 11172164
-
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340
-
(2001)
N Engl J Med
, vol.344
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
33
-
-
12944291524
-
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
-
COI: 1:CAS:528:DC%2BD3cXhvFGgsr0%3D, PID: 10663363
-
Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91
-
(2000)
Osteoporos Int
, vol.11
, pp. 83-91
-
-
Reginster, J.Y.1
Minne, H.W.2
Sorensen, O.H.3
-
34
-
-
4544262219
-
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
-
COI: 1:CAS:528:DC%2BD2cXntFGqurw%3D
-
Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249
-
(2004)
J Bone Miner Res
, vol.19
, pp. 1241-1249
-
-
Chesnut, C.H.1
Skag, A.2
Christiansen, C.3
-
35
-
-
34247866550
-
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
COI: 1:CAS:528:DC%2BD2sXltVSktLc%3D, PID: 17476007
-
Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822
-
(2007)
N Engl J Med
, vol.356
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
-
36
-
-
35748967004
-
Zoledronic acid and clinical fractures and mortality after hip fracture
-
COI: 1:CAS:528:DC%2BD2sXht1Kit7nN, PID: 17878149
-
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
-
(2007)
N Engl J Med
, vol.357
, pp. 1799-1809
-
-
Lyles, K.W.1
Colón-Emeric, C.S.2
Magaziner, J.S.3
-
37
-
-
0035999440
-
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension
-
COI: 1:CAS:528:DC%2BD38Xks1Wktb0%3D, PID: 12054161
-
Brumsen C, Papapoulos SE, Lips P et al (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057–1064
-
(2002)
J Bone Miner Res
, vol.17
, pp. 1057-1064
-
-
Brumsen, C.1
Papapoulos, S.E.2
Lips, P.3
-
38
-
-
3242784254
-
Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study
-
COI: 1:CAS:528:DC%2BD2cXktFGksrs%3D, PID: 15068495
-
McCloskey E, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 19:728–736
-
(2004)
J Bone Miner Res
, vol.19
, pp. 728-736
-
-
McCloskey, E.1
Selby, P.2
Davies, M.3
-
39
-
-
33845922409
-
Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo controlled randomized study
-
COI: 1:CAS:528:DC%2BD2sXhtVWnurs%3D, PID: 17042717
-
McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo controlled randomized study. J Bone Miner Res 22:135–141
-
(2007)
J Bone Miner Res
, vol.22
, pp. 135-141
-
-
McCloskey, E.V.1
Beneton, M.2
Charlesworth, D.3
-
40
-
-
84911809814
-
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
-
Coleman R, de Boer R, Eidtmann H et al (2012) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol [Epub ahead of print]
-
(2012)
Ann Oncol [Epub ahead of print]
-
-
Coleman, R.1
De Boer, R.2
Eidtmann, H.3
-
41
-
-
84862926420
-
Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial
-
COI: 1:CAS:528:DC%2BC38Xht1OnsLc%3D, PID: 22014381
-
Llombart A, Frassoldati A, Paija O et al (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12:40–48
-
(2012)
Clin Breast Cancer
, vol.12
, pp. 40-48
-
-
Llombart, A.1
Frassoldati, A.2
Paija, O.3
-
42
-
-
84857370664
-
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
-
COI: 1:CAS:528:DC%2BC38XisVyiu7Y%3D, PID: 21987386
-
Brufsky AM, Harker WG, Beck JT et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118:1192–1201
-
(2012)
Cancer
, vol.118
, pp. 1192-1201
-
-
Brufsky, A.M.1
Harker, W.G.2
Beck, J.T.3
-
43
-
-
84887102978
-
Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature
-
COI: 1:STN:280:DC%2BC2c7jt1OitA%3D%3D, PID: 24192561
-
Varenna M, Bertoldo F, Di Monaco M, Giusti A, Martini G, Rossini M (2013) Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo 65:143–166
-
(2013)
Reumatismo
, vol.65
, pp. 143-166
-
-
Varenna, M.1
Bertoldo, F.2
Di Monaco, M.3
Giusti, A.4
Martini, G.5
Rossini, M.6
-
44
-
-
84860839841
-
Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC38XlsVaisr8%3D, PID: 22465268
-
Grey A, Bolland MJ, Horne A et al (2012) Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial. Bone 50:1389–1393
-
(2012)
Bone
, vol.50
, pp. 1389-1393
-
-
Grey, A.1
Bolland, M.J.2
Horne, A.3
-
45
-
-
84856184102
-
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
-
COI: 1:CAS:528:DC%2BC38XhtV2ks7g%3D, PID: 22161728
-
Black DM, Reid IR, Boonen S et al (2012) The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 27:243–254
-
(2012)
J Bone Miner Res
, vol.27
, pp. 243-254
-
-
Black, D.M.1
Reid, I.R.2
Boonen, S.3
-
46
-
-
33845890326
-
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
-
COI: 1:CAS:528:DC%2BD2sXnvVGh, PID: 17190893
-
Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938
-
(2006)
JAMA
, vol.296
, pp. 2927-2938
-
-
Black, D.M.1
Schwartz, A.V.2
Ensrud, K.E.3
-
47
-
-
84868200577
-
Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome
-
COI: 1:CAS:528:DC%2BC38XhsFygu7rO, PID: 22966867
-
Chatterjee R, Shah FT, Davis BA et al (2012) Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 159:462–471
-
(2012)
Br J Haematol
, vol.159
, pp. 462-471
-
-
Chatterjee, R.1
Shah, F.T.2
Davis, B.A.3
|